Product Images Desvenlafaxine

The text seems to be a table showing the estimated proportion of patients experiencing relapse over time, measured in days from randomization, while taking either Desvenlafaxine extended-release tablets at a dose of 50mg or a placebo. The percentages of patients with relapse are listed on the left side of the table, while the time to relapse is denoted along the bottom.*

This appears to be a graph or chart showing the estimated proportion of patients with relapse over time for the drug Desvenlafaxine Extended Release Tablets compared to a placebo. The X-axis shows the time to relapse in days from randomization, while the Y-axis shows percentages ranging from 10% to 50%. The graph displays two lines, one for Desvenlafaxine and one for placebo. This could be useful for healthcare professionals in determining the efficacy of Desvenlafaxine in preventing relapse in patients.*

Each tablet contains 152 mg desvenlafaxine. The Desvenlafaxine tablet should be swallowed whole and not crushed or chewed. Extended-release tablets should be stored between 20 to 25°C (68° to 77°F) and excursions permitted from 15° to 30°C (59° to 86°F). There is a medication guide provided separately to each patient. The pharmacist should dispense with the medication and keep it out of reach and sight of children. For any questions or concerns, please contact Inteliphamaceutics Corp. The description seems to be for a medication, and we do not have information on what it is used for.*

This is a medication for Desvenlafaxine with instructions to swallow the extended-release tablets whole and store it at a particular temperature range. It also includes a caution for pharmacists to explain the medication to patients and keep it out of reach of children. The medication comes in a 14 tablet pack and is only available with a prescription. The text is readable.*

This text appears to provide information on the impact of CYP3A4 inhibitors, specifically Ketoconazole, on the geometric mean ratio of Change Duelo K, as well as the change relative to reference. The Cmax and AUC values are also mentioned in the context of this study. However, the specific context of this study and the implications of these findings are not clear.*

This is a table that shows the geometric mean ratio (90% CI) of PK parameters for a medication in different populations. The first part shows the ratios for patients with renal impairment of varying degrees, while the second part shows the ratios for patients with hepatic impairment. The final section shows the ratios for different demographic groups, including gender and age. The medication's Cmax and AUC values are listed, along with the degree of change relative to the reference group. The table also provides an explanation of the abbreviation "ESRD," which stands for End Stage Renal Disease.*